Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Pres. Fredrickson Leaves AZ Japan Unit after 14 Months in Office
September 11, 2017
- Canalia, Japan’s 1st DPP-4/SGLT-2 Combo, Now Available
September 8, 2017
- Ethical Drug Sales Rise 0.4% in July: Crecon
September 8, 2017
- PI Starts in US for Daiichi Sankyo/Sanford Burnham’s TNAP Inhibitor
September 8, 2017
- Japan PIII for Atopic Dermatitis Drug Nemolizumab to Begin in October: Maruho
September 8, 2017
- Chugai to Expand Range of Drugs on Its Medication Optimization Support Application
September 8, 2017
- Sumitomo Dainippon Licenses Antiemetic to Maruishi in Japan, US
September 7, 2017
- Eisai, Merck to Expand Enrollment of Keytruda Combination Trials with Lenvima/Halaven
September 6, 2017
- Japanese Drug Majors Ratcheting Up Moves in CAR-T Space
September 6, 2017
- Spera Pharma Begins Business Capitalizing on “Takeda’s” Track Record, Aims to Become Japan’s No. 1 CDMO
September 6, 2017
- Takeda in CAR-T Therapy Pact with NCC/Yamaguchi Univ. Spin-Out
September 5, 2017
- Mitsubishi Tanabe to Beef Up Marketing System in Field of Autoimmune Diseases, Plans to Expand Expert Sales Force
September 5, 2017
- Aspen Completes Takeover of 4 Kyowa Kirin Brands
September 4, 2017
- BIKEN-Mitsubishi Tanabe Vaccine JV Now Up and Running
September 4, 2017
- Seikagaku, Ono Ink Definitive Deal on Osteoarthritis Treatment
September 4, 2017
- Yamaha Enters Medical Field with Cell Handler, a Device to Support Drug Discovery
September 4, 2017
- Mirogabalin Delivers Positive Data for Diabetic Peripheral Neuropathic Pain: Daiichi Sankyo
September 1, 2017
- Daiichi Sankyo Ditches CL-108 Deal, Takes 27.8 Billion Yen Impaired Loss
September 1, 2017
- Daiichi Sankyo Denies Report on AZ’s Acquisition Offer
September 1, 2017
- Opdivo Clinches Batch of New Indications in South Korea
August 31, 2017
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…